Phibro Animal Health financials
$35.45−0.70%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY23 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 | FY19 Jun 30 | FY18 Jun 30 | FY17 Jun 30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.52B | $1.30B | $1.02B | $977.9M | $942.3M | $833.4M | $800.4M | $828.0M | $820.0M | $764.3M |
| Gross profit | $512.5M | $399.9M | $313.1M | $298.2M | $285.4M | $271.4M | $256.9M | $264.6M | $266.9M | $248.2M |
| Gross margin | 33.8% | 30.9% | 30.8% | 30.5% | 30.3% | 32.6% | 32.1% | 32.0% | 32.5% | 32.5% |
| Operating income | $194.4M | $110.5M | $53.3M | $71.8M | $79.0M | $74.9M | $69.2M | $83.2M | $98.9M | $97.9M |
| Net income | $99.7M | $48.3M | $2.4M | $32.6M | $49.2M | $54.4M | $33.6M | $54.7M | $64.9M | $64.6M |
| Net margin | 6.6% | 3.7% | 0.2% | 3.3% | 5.2% | 6.5% | 4.2% | 6.6% | 7.9% | 8.5% |
| Diluted EPS | $2.43 | $1.19 | $0.06 | $0.81 | $1.21 | $1.34 | $0.83 | $1.35 | $1.61 | $1.61 |
| EBITDA | $245.9M | $156.1M | $89.5M | $105.9M | $111.7M | $106.8M | $101.5M | $110.8M | $125.9M | $123.9M |
| Operating cash flow | $69.0M | $80.1M | $87.6M | $13.3M | $31.6M | $48.3M | $59.3M | $47.2M | $70.0M | $98.4M |
| Free cash flow | $9.9M | $41.8M | $46.4M | -$38.5M | -$5.4M | $19.0M | $25.3M | $17.3M | $51.5M | $77.5M |
| Diluted shares | 41.0M | 40.7M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.4M | 40.0M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $61.4M | $68.0M | $70.6M | $41.3M | $74.2M | $50.2M |
| Short-term investments | $20.6M | $9.0M | $44.0M | $40.0M | $17.0M | $43.0M |
| Total debt | $732.8M | $718.7M | $488.1M | $474.8M | $432.9M | $392.1M |
| Total assets | $1.50B | $1.36B | $982.2M | $971.4M | $931.7M | $841.3M |
| Total liabilities | $1.12B | $1.08B | $725.5M | $688.9M | $669.3M | $602.8M |
| Shareholders' equity | $385.5M | $285.7M | $256.6M | $282.5M | $262.4M | $238.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology